Press release
Advanced Recurrent Ovarian Cancer Advanced Recurrent Ovarian Cancer Pipeline Drugs Insights Report 2025: Next-Gen Therapies and Ongoing Clinical Trials Drive Market Growth | DelveInsight
Curious about the latest updates in the Advanced Recurrent Ovarian Cancer Pipeline? Click here to explore the therapies and trials making headlines @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report
* On 30 October 2025, Merck Sharp & Dohme LLC conducted a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
* On 30 October 2025, University of Colorado, Denver conducted a Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
* On 27 October 2025, Compugen Ltd conducted a clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701.
* DelveInsight's Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
* The leading Advanced Recurrent Ovarian Cancer Companies such as Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
* Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin , and others.
Want to know which companies are leading innovation in Advanced Recurrent Ovarian Cancer? Dive into the full pipeline insights @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Advanced Recurrent Ovarian Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Advanced Recurrent Ovarian Cancer Pipeline Report also highlights the unmet needs with respect to the Advanced Recurrent Ovarian Cancer.
Advanced Recurrent Ovarian Cancer Overview
Advanced Recurrent Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer.
Advanced Recurrent Ovarian Cancer Emerging Drugs
* 2X-121: Allarity Therapeutics
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity's Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.
* A2B694: A2 Biotherapeutics Inc.
A2B694 is a Tmod Trademark chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod Trademark platform. The Tmod Trademark platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express mesothelin and have lost the HLA-A*02 gene permanently. This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines - the ability to selectively kill tumor cells and protect normal cells. Currently, the drug is in Phase I/II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.
* ATX-295: Accent Therapeutics
Accent's ATX-295 program is a potential best-in-class inhibitor for KIF18A which may address a large patient population across several cancer indications, including ovarian and triple negative breast cancer (TNBC). KIF18A is a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability, but not in healthy cells. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. Currently, the drug is in Phase I stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.
If you're tracking ongoing Advanced Recurrent Ovarian Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Advanced Recurrent Ovarian Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Advanced Recurrent Ovarian Cancer Companies
Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
The Advanced Recurrent Ovarian Cancer Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
* Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.
Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Advanced Recurrent Ovarian Cancer Pipeline Report covers it all - check it out now @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report
* Coverage- Global
* Advanced Recurrent Ovarian Cancer Companies- Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
* Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin , and others.
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in oncology research - discover what's next for the Advanced Recurrent Ovarian Cancer Treatment landscape in this detailed analysis @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Advanced Recurrent Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Recurrent Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* 2X-121: Allarity Therapeutics
* Early Stage Products (Phase I)
* ATX-295: Accent Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Advanced Recurrent Ovarian Cancer Key Companies
* Advanced Recurrent Ovarian Cancer Key Products
* Advanced Recurrent Ovarian Cancer- Unmet Needs
* Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
* Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
* Advanced Recurrent Ovarian Cancer Analyst Views
* Advanced Recurrent Ovarian Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-recurrent-ovarian-cancer-advanced-recurrent-ovarian-cancer-pipeline-drugs-insights-report-2025-nextgen-therapies-and-ongoing-clinical-trials-drive-market-growth-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Recurrent Ovarian Cancer Advanced Recurrent Ovarian Cancer Pipeline Drugs Insights Report 2025: Next-Gen Therapies and Ongoing Clinical Trials Drive Market Growth | DelveInsight here
News-ID: 4251882 • Views: …
More Releases from ABNewswire
Weissman | Paul Advises Central Florida Families to Revisit Estate Plans and Pro …
Altamonte Springs, FL - November 3, 2025 - With the year drawing to a close and 2026 on the horizon, Weissman | Paul is encouraging families across Central Florida to take a fresh look at their estate plans and probate preparedness. The Altamonte Springs-based law firm, known for its trusted probate and estate planning services, emphasizes that even well-intentioned plans can become outdated-potentially creating complications for loved ones down the…
Vacation Safeguard Joins GNEX-ACOTUR 2025 Conference as Gold Sponsor
Loyalty Guarantee Provider Backs Key Industry Event Uniting Leaders Across Latin America and Beyond
Orlando, Fla. - November 3, 2025 - The Association of Vacation and Tourism Complexes (ACOTUR) and Perspective Group today announced that Vacation SafeGuard has joined as a Gold Sponsor of the GNEX-ACOTUR 2025 Conference, taking place November 18-20 at the Kempinski Hotel in Cancun, Mexico. GNEX-short for Global Networking Experience-is a series of high-level industry events designed…
Hanley Investment Group Launches 15th Annual Movember Campaign with "Mo'ments in …
CORONA DEL MAR, Calif. - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, proudly kicks off its 15th annual Movember fundraising campaign, "Mo'ments in Time," in celebration of the firm's 20th anniversary.
Since 2011, Hanley Investment Group has raised $400,000 for Movember, the leading global charity dedicated to improving men's health through awareness and funding for prostate cancer, testicular…
Elizabeth Townsend Unveils New Single "My Thoughts Exactly"
Image: https://www.abnewswire.com/upload/2025/11/8ae11ecea242a180bd60f2bdfeec24c8.jpg
YAKIMA, WASHINGTON - The acclaimed Christian Country Gospel artist known for her Songwriting of Christian Gospel Music with her first studio recording in 1988, when she released her first single I Find No Fault In My King Jesus. Submitted to BMI along with her other 25 musical compositions. You can also read MYKING JESUS, the true autobiography of Lady Elizabeth Townsend, on Amazon.com, along with eight other titles.
Lady Elizabeth…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
